| Sun, Lingyun |
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease |
|
|
| Recruiting | 3 | 440 | Europe, Japan, US, RoW | Belimumab, BENLYSTA, GSK1550188, Placebo | GlaxoSmithKline | Lung Diseases, Interstitial | 10/28 | 12/28 | | |
NCT06716606: A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease |
|
|
| Recruiting | 3 | 225 | RoW | Belimumab | GlaxoSmithKline, ICON plc | Bronchial Diseases | 08/28 | 01/30 | | |
| Recruiting | 2/3 | 240 | Europe, Canada, Japan, US, RoW | EFG PH20 SC, PBO | argenx, argenx BV | Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome | 12/26 | 02/27 | | |
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease |
|
|
| Recruiting | 2/3 | 300 | Europe, Japan, US, RoW | Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo | GlaxoSmithKline | Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic | 07/27 | 07/27 | | |
|
NCT04830644: A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome. |
|
|
| Recruiting | 2 | 144 | RoW | Iguratimod, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Primary Sjögren Syndrome | 04/22 | 06/22 | | |
NCT06222671: A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA) |
|
|
| Not yet recruiting | 2 | 180 | RoW | 608, Placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Axial Spondyloarthritis | 11/25 | 11/25 | | |
NCT05849727: A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis |
|
|
| Recruiting | 2 | 180 | RoW | TQH3821 tablets 200 mg, TQH3821 tablets matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Rheumatoid Arthritis | 06/24 | 12/24 | | |
| Completed | 2 | 456 | Europe, Japan, US, RoW | Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Systemic Lupus Erythematosus | 11/24 | 11/24 | | |
|
|
NCT06058078: RY_SW01 Cell Injection Therapy in Active Lupus Nephritis |
|
|
| Recruiting | 2 | 60 | RoW | RY_SW01 cell injection, UC-MSC treatment, Basic treatment, Immunosuppressive drugs | Jiangsu Renocell Biotech Company, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Lupus Nephritis | 12/25 | 12/28 | | |
NCT06717815: Phase Ib/IIa Study for IPG11406 in Patients with Lupus Nephritis |
|
|
| Not yet recruiting | 1/2 | 36 | RoW | IPG11406 | Nanjing Immunophage Biotech Co., Ltd | Lupus Nephritis | 11/25 | 04/26 | | |
NCT04457856: A Study of TJ003234 in Rheumatoid Arthritis Patients |
|
|
| Recruiting | 1 | 63 | RoW | TJ003234 injection | I-Mab Biopharma Co. Ltd. | Rheumatoid Arthritis | 03/23 | 03/23 | | |
NCT06340490: A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE) |
|
|
| Not yet recruiting | 1 | 24 | RoW | RJMty19 (CD19-CAR-DNT cells), Fludarabine, Cyclophosphamide | Guangdong Ruishun Biotech Co., Ltd, RenJi Hospital, Peking University People's Hospital, Changhai Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Systemic Lupus Erythematosus | 12/26 | 12/27 | | |
| Li, Jie |
| Active, not recruiting | 4 | 640 | RoW | Tenofovir Amibufenamide（TMF）, HS-10234 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Hepatitis B, Chronic | 06/24 | 09/29 | | |
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 336 | Canada, RoW | Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2 | Reistone Biopharma Company Limited | Atopic Dermatitis | 08/22 | 05/23 | | |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
| Not yet recruiting | 3 | 358 | RoW | TQB2450+Anlotinib, TQB2450 placebo + Anlotinib placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Small Cell Lung Cancer Limited Stage | 09/26 | 09/26 | | |
NCT04983043: Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure |
|
|
| Completed | 2 | 228 | RoW | Low dose QiShen YiQi Dripping Pills 3 bags, Low dose group, High dose QiShen YiQi Dripping Pills 3 bags, High dose group, QiShen YiQi Dripping Pills placebo 3 bags, Placebo group | Tasly Pharmaceutical Group Co., Ltd | Chronic Heart Failure With Reduced Ejection Fraction | 11/24 | 11/24 | | |
NCT06566248: A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B |
|
|
| Recruiting | 2 | 90 | RoW | TQA3810 tablets+NUC, Placebo+NUC | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Hepatitis B | 09/24 | 03/25 | | |
NCT06241781: Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer |
|
|
| Recruiting | 2 | 64 | RoW | GT101 injection, Gemcitabine injection | Grit Biotechnology | Adult | 01/27 | 01/27 | | |
| Recruiting | 2 | 270 | RoW | TQB2102 for injection, TQB2102 for injection combined with Benmelstobart injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Non-Small Cell Lung Cancer | 10/25 | 02/26 | | |
NCT05632861: HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR) |
|
|
| Recruiting | 2 | 76 | RoW | HuHuangLianzonggan capsule, Experimental group, HuHuangLianzonggan capsule placebo, Placebo group | Tasly Pharmaceutical Group Co., Ltd | NASH | 12/24 | 12/24 | | |
TQB3909-Ib/II-02, NCT05959694: A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . |
|
|
| Recruiting | 1/2 | 107 | RoW | TQB3909 tablet | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/25 | 06/26 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
| Recruiting | N/A | 500 | US | | COPD Foundation, Viatris Inc. | COPD | 12/24 | 07/25 | | |
EFLRWR, NCT05132218: Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 180 | RoW | Ensatinib, BD-EN-IV002 | Beijing Cancer Hospital, Betta Pharmaceuticals Co., Ltd. | ALK Positive, NSCLC Stage IIIB, NSCLC Stage IV | 10/22 | 10/24 | | |
| Zhu, Dalong |
NCT04373967: Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes |
|
|
| Recruiting | 3 | 424 | RoW | Victoza®., Metformin Hydrochloride, TQZ2451 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Type 2 Diabetes | 12/21 | 12/21 | | |
NCT05628311: A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise |
|
|
| Completed | 3 | 319 | RoW | placebo, IBI362 | Innovent Biologics (Suzhou) Co. Ltd. | Type 2 Diabetes | 10/23 | 05/24 | | |
NCT06339086: Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes |
|
|
| Not yet recruiting | 3 | 478 | NA | Semaglutide Injection, Semaglutide Injection(Ozempic®), Ozempic®, Metformin, Glucophage® | Chengdu Brilliant Pharmaceutical Co., Ltd. | Type 2 Diabetes Mellitus | 08/25 | 12/25 | | |
NCT05680155: A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients |
|
|
| Active, not recruiting | 3 | 211 | RoW | Ecnoglutide, XW003, Placebo | Hangzhou Sciwind Biosciences Co., Ltd. | T2DM, Type 2 Diabetes Mellitus | 10/24 | 10/24 | | |
NCT05063253: A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes |
|
|
| Not yet recruiting | 2 | 208 | NA | TG103, Administered SC, Placebo | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Type 2 Diabetes Mellitus | 03/24 | 03/24 | | |
| Du, Juan |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 5 | RoW | Fluzoparib, SHR3162, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Pancreatic Cancer | 02/22 | 02/22 | | |
NCT06305104: Clinical Trial to Explore the Skin Test Dosage of EEC in People Aged 18 to 65 Years Old and the Safety and Preliminary Efficacy in People Aged 3 to 75 Years Old. |
|
|
| Recruiting | 2 | 420 | RoW | 2.5μg/ml EEC, 5μg/ml EEC, 5 unit（U） EC | Chengdu CoenBiotech Co., Ltd, Beijing Chest Hospital, Capital Medical University, Wuhan Institute for Tuberculosis Control, The Public Health Clinical Center of Chengdu, Xuzhou Infectious Disease Hospital, Jiangsu Province Centers for Disease Control and Prevention, Changde First People's Hospital | Tuberculosis | 05/24 | 06/24 | | |
PAAG, NCT05493995: A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer. |
|
|
| Completed | 2 | 66 | RoW | Penpulimab, AK105, Anlotinib, Nab paclitaxel, Gemcitabine | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pancreatic Neoplasms | 05/24 | 05/24 | | |
NCT05594797: Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM |
|
|
| Recruiting | 2 | 100 | RoW | Human BCMA Targeted T Cells Injection, BCMA CAR-T | Hrain Biotechnology Co., Ltd., Shanghai Changzheng Hospital, First Affiliated Hospital of Wenzhou Medical University | Multiple Myeloma | 07/25 | 07/27 | | |
| Recruiting | 1/2 | 20 | RoW | GC012F injection | Shanghai Changzheng Hospital, Gracell Biotechnology Shanghai Co., Ltd. | Multiple Myeloma | 07/23 | 07/23 | | |
NCT05302648: To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM |
|
|
| Active, not recruiting | 1 | 18 | RoW | Human Derived anti-BCMA CAR-T Injection, BCMA CAR-T | Hrain Biotechnology Co., Ltd., Shanghai Changzheng Hospital | Multiple Myeloma | 12/24 | 12/25 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
NCT05412329: Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma |
|
|
| Recruiting | 1 | 9 | RoW | GC012F injection | Shanghai Changzheng Hospital, Gracell Biotechnology Shanghai Co., Ltd. | Multiple Myeloma | 06/24 | 06/24 | | |
NCT06407947: Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma |
|
|
| Recruiting | 1 | 10 | RoW | Chimeric antigen receptor modified T cells Infusion, Single Group Assignment | Shanghai Changzheng Hospital, CARsgen Therapeutics Co., Ltd. | Multiple Myeloma | 06/27 | 06/27 | | |
| Active, not recruiting | 1 | 20 | RoW | Experimental: CAR-T cells Infusion, Single Group Assignment | Shanghai Changzheng Hospital, CARsgen Therapeutics Co., Ltd. | Multiple Myeloma, Primary Plasma Cell Leukemia | 07/25 | 07/25 | | |
NCT06718270: a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia |
|
|
| Recruiting | 1 | 24 | RoW | CAR-T cells Infusion | Shanghai Changzheng Hospital, CARsgen Therapeutics Co., Ltd. | Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Plasma Cell Leukemia | 01/27 | 12/27 | | |
NCT05840107: Study of FasT CAR-T GC012F Injection NDMM Patients |
|
|
| Recruiting | 1 | 18 | RoW | GC012F injection | Shanghai Changzheng Hospital, Gracell Biotechnology Shanghai Co., Ltd. | Multiple Myeloma | 09/25 | 09/25 | | |
NCT06045091: To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL |
|
|
| Recruiting | 1 | 18 | RoW | Human BCMA targeted CAR-NK cells injection, BCMA CAR-NK | Hrain Biotechnology Co., Ltd., Shanghai Changzheng Hospital | Multiple Myeloma, Plasma Cell Leukemia | 09/25 | 09/27 | | |
| Li, Juan |
NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 3 | 85 | RoW | Pomalidomide, Dexamethasone | Qilu Pharmaceutical Co., Ltd. | Multiple Myeloma, Recurrent or Refractory | 06/22 | 12/23 | | |
FGCL-4592-898, NCT05301517: A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies |
|
|
| Completed | 3 | 159 | RoW | SEPO®, Recombinant human erythropoietin-α [rHuEPO-α], Roxadustat, FG-4592 | FibroGen | Chemotherapy Induced Anemia | 04/23 | 04/23 | | |
NCT06631170: Efficacy and Safety of Roflumilast Cream in Subjects with Atopic Dermatitis |
|
|
| Recruiting | 3 | 351 | RoW | Roflumilast Cream 0.15%, Vehicle cream | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Atopic Dermatitis (AD) | 08/25 | 08/25 | | |
| Recruiting | 3 | 472 | RoW | Qingzhu Granules, Qingzhu Granules Placebo | Tasly Pharmaceutical Group Co., Ltd | Gouty Arthritis | 10/25 | 10/25 | | |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
NCT05247216: A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis |
|
|
| Completed | 2 | 140 | RoW | Hemay007 800 mg QD group, Hemay007 1200 mg QD group, Hemay007 600 mg QD group, Hemay007 placebo group | Tianjin Hemay Pharmaceutical Co., Ltd | Rheumatoid Arthritis | 06/23 | 06/23 | | |
NCT04674514: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 48 | RoW | APG-2575, Rd, Lenalidomide +Dexamethasone | Ascentage Pharma Group Inc. | Multiple Myeloma | 01/24 | 05/24 | | |
NCT05565807: Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 84 | RoW | STI-6129 | Zhejiang ACEA Pharmaceutical Co. Ltd. | Relapsed or Refractory Multiple Myeloma | 03/25 | 02/27 | | |
NCT06388772: Study to Assess PK, Safety and Tolerability Early in Healthy Subjects |
|
|
| Completed | 1 | 74 | RoW | QHRD106 Injection, pegylated(PEG)-tissue kallikrein-1, placebo | Changzhou Qianhong Bio-pharma Co., Ltd. | Acute Ischemic Stroke | 07/22 | 01/23 | | |
NCT06380699: Study to Assess PK, Safety and Tolerability in Healthy Subjects |
|
|
| Completed | 1 | 56 | RoW | QHRD106 Injection, pegylated(PEG)-tissue kallikrein-1, Human Urinary Kallidinogenase, tissue kallikrein-1, placebo | Changzhou Qianhong Bio-pharma Co., Ltd. | Acute Ischemic Stroke | 11/23 | 12/23 | | |
NCT06326723: Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects |
|
|
| Completed | 1 | 32 | RoW | Daridorexant | Jiangsu Simcere Pharmaceutical Co., Ltd. | Healthy Volunteer | 12/23 | 02/24 | | |
NCT06137469: Assessment of Gastric Emptying by SHR20004 in Healthy Subjects |
|
|
| Completed | 1 | 28 | RoW | Acetaminophen/SHR20004, Acetaminophen/Placebo | Jiangsu HengRui Medicine Co., Ltd. | Type 2 Diabetes Mellitus | 03/24 | 03/24 | | |
| Completed | 1 | 34 | RoW | Itraconazole+TGRX-326, Efavirenz+TGRX-326 | Shenzhen TargetRx, Inc., The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Non Small Cell Lung Cancer | 05/24 | 05/24 | | |
NCT06536400: Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation |
|
|
| Recruiting | 1 | 316 | RoW | HSK42360 | Haisco Pharmaceutical Group Co., Ltd. | Solid Tumors | 08/26 | 07/27 | | |
NCT06615193: A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor |
|
|
| Recruiting | 1 | 111 | RoW | HDM2005 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Advanced Solid Tumors, Refractory Lymphoma, Relapsed Hematologic Malignancy | 06/26 | 02/28 | | |
NCT06662760: Clinical Trial of TQB3002 in Patients With Advanced Cancers |
|
|
| Not yet recruiting | 1 | 120 | RoW | TQB3002 Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Cancer | 10/25 | 10/26 | | |
| Wang, Hao |
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 3 | 274 | RoW | BPI-16350, placebo, Fulvestrant | Betta Pharmaceuticals Co., Ltd. | Breast Cancer | 12/23 | 07/25 | | |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NCT04927481: A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer |
|
|
| Terminated | 2 | 28 | RoW | Mitoxantrone Hydrochloride Liposome Injection | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Breast Cancer | 01/23 | 01/23 | | |
| Dai, Yutian |
NCT05188989: Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction. |
|
|
| Completed | 3 | 765 | RoW | TPN171H 2.5mg group, Simmerafil, TPN171H 5mg group, TPN171H 10mg group, Placebo group | Vigonvita Life Sciences | Erectile Dysfunction | 02/23 | 02/23 | | |
NCT05388825: Pharmacodynamic Study of TPN171H Tablets in Patients With Mild to Moderate Erectile Dysfunction |
|
|
| Completed | 2 | 84 | RoW | TPN171H 2.5mg, TPN171H 5mg, TPN171H 10mg, Placebo 5mg, Placebo 10mg | Vigonvita Life Sciences | Erectile Dysfunction | 01/23 | 02/23 | | |
| Liang, Jun |
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 560 | RoW | Irinotecan Hydrochloride Injection, HX008, Placebo | Taizhou Hanzhong biomedical co. LTD | Stomach Cancer | 08/23 | 08/23 | | |
HLX10-006-GCneo, NCT04139135: A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer |
|
|
| Recruiting | 3 | 642 | RoW | HLX10, Recombinant humanized anti-PD-1 monoclonal antibody injection, Placebos | Shanghai Henlius Biotech | Gastric Cancer | 10/23 | 10/24 | | |
NCT06738979: A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects |
|
|
| Not yet recruiting | 3 | 408 | RoW | TQF3510 (Semaglutide Injection), Wegovy® | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Obesity | 07/26 | 08/26 | | |
NCT04291248: A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor |
|
|
| Not yet recruiting | 2 | 138 | RoW | AK105, Anlotinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | MSI-H or dMMR Advanced Solid Tumors | 12/22 | 12/22 | | |
NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy |
|
|
| Recruiting | 2 | 108 | RoW | HLX10 | Shanghai Henlius Biotech | MSI-H Solid Malignant Tumor | 05/24 | 06/26 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 02/25 | 05/25 | | |
| Wu, Chao |
NCT04147208: Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection |
|
|
| Completed | 2 | 250 | RoW | GLS4, Morphothiadine Mesilate Capsules, RTV, Ritonavir tablet, ETV, Entecavir table | Sunshine Lake Pharma Co., Ltd. | Chronic HBV Infection | 06/22 | 09/23 | | |
C-DIAMOND, NCT04952207: Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C |
|
|
| Recruiting | N/A | 300 | RoW | Direct-acting antiviral agents, daclatasvir, asunaprevir, ombitasvir, paritaprevir, dasabuvir, sofosbuvir, velpatasvir, ledipasvir, elbasvir, grazoprevir, danoprevir, glecaprevir, pibrentasvir, voxilaprevir | Qing XIe, Gilead Sciences, Tigermed Consulting Co., Ltd | Hepatitis C, Chronic | 07/21 | 08/21 | | |
| Wang, Dongjin |
| Recruiting | 1/2 | 20 | RoW | hPSC-CM Therapy | Help Therapeutics, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Heart Failure | 04/24 | 10/24 | | |
| Recruiting | N/A | 120 | RoW | Transcatheter aortic valve replacement | Genesis Medtech Corporation | Diseases of Aortic Valve, Aortic Regurgitation Disease | 05/23 | 05/24 | | |
NCT05607667: Clinical Trial in China for Aortic Valve Stenosis |
|
|
| Recruiting | N/A | 53 | RoW | Transcatheter aortic valve replacement | Genesis Medtech Corporation | Diseases of Aortic Valve, Aortic Stenosis Disease | 05/23 | 05/23 | | |
| Guo, Hongqian |
TQB2450-III-07, NCT04523272: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer |
|
|
| Active, not recruiting | 3 | 528 | RoW | TQB2450, Anlotinib, Sunitinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Renal Cancer | 06/25 | 12/25 | | |
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer |
|
|
| Active, not recruiting | 3 | 496 | Europe, US, RoW | Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 12/26 | 12/26 | | |
| Active, not recruiting | 2/3 | 350 | Europe, Japan, US, RoW | Abemaciclib, LY2835219, Abiraterone Acetate, Prednisone, Placebo | Eli Lilly and Company | Prostate Cancer | 01/24 | 06/26 | | |
| Recruiting | 2 | 240 | Europe, Canada, US, RoW | SKB264, Pembrolizumab, Keytruda | Klus Pharma Inc., Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc. | Solid Tumor | 11/26 | 12/27 | | |
ARES, NCT05778097: Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence ( Study) |
|
|
| Not yet recruiting | 2 | 103 | RoW | Apalutamide 60mg Tab, Androgen deprivation therapy(ADT) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Xian-Janssen Pharmaceutical Ltd. | Prostate Cancer, Biochemical Recurrence, High Risk | 08/26 | 12/26 | | |
NCT05253053: To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 114 | RoW | TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel | TransThera Sciences (Nanjing), Inc. | Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer | 09/24 | 12/24 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT06220838: Study SC-101 in Subjects with Advanced Malignancies |
|
|
| Recruiting | 1 | 100 | RoW | SC-101 | Tianjin ConjuStar Biologics Co., Ltd. | Advanced Solid Tumor | 06/25 | 12/25 | | |
NCT05973149: Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer |
|
|
| Not yet recruiting | 1 | 108 | RoW | QLH12016 | Qilu Pharmaceutical Co., Ltd. | Prostate Cancer | 08/25 | 01/26 | | |
| Li, Xiaoqiang |
NCT05430672: Safety and Efficacy Study Of The Thoracic Aortic Stent Graft System Treating Aortic Dissection |
|
|
| Not yet recruiting | N/A | 120 | RoW | The Thoracic Aortic Stent Graft System (Zylox-Tonbridge Medical Technology Co., Ltd. ) | Zhejiang Zylox Medical Device Co., Ltd. | Aortic Dissection | 08/23 | 08/24 | | |
NCT05415995: A Trail of Drug-coated Balloon Treating Below The Knee Arterial Diseases |
|
|
| Recruiting | N/A | 202 | RoW | Drug eluting Balloon | Zhejiang Zylox Medical Device Co., Ltd. | Peripheral Artery Disease | 12/23 | 12/24 | | |
PINTO, NCT05562076: Clinical Study of Focal Implant Used for Lower Extremity Post-angioplasty Dissection |
|
|
| Not yet recruiting | N/A | 224 | RoW | the spot stent(ZENFLEX ® Pinto) system, the bare stent( Everflex) system | Zhejiang Zylox Medical Device Co., Ltd. | Peripheral Artery Disease | 02/24 | 02/25 | | |
GENIUS, NCT04849325: IBS Titan vs. PTA in Patients With Infrapopliteal Arterial Stenosis or Occlusive Disease |
|
|
| Recruiting | N/A | 120 | RoW | Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titanâ„¢), Percutaneous Transluminal Angioplasty (PTA) Device | Biotyx Medical (Shenzhen) Co., Ltd. | Critical Limb Ischemia (CLI) | 04/24 | 10/24 | | |
| Not yet recruiting | N/A | 342 | RoW | Osimertinib, Alectinib, TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy | Guangdong Association of Clinical Trials, Nanjing Geneseeq Technology Inc. | Non-Small Cell Lung Cancer | 01/29 | 01/32 | | |
| Zhuang, Junlong |
PROact, NCT05167175: The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation |
|
|
| Recruiting | 2 | 30 | RoW | Olaparib tablet, Lynparza, Abiraterone acetate, Qingkeshu, Prednisone tablet | Hongqian Guo, AstraZeneca, Nanjing Chia-tai Tianqing Pharmaceutical | Prostate Cancer, Prostate Carcinoma, Metastatic Prostate Cancer | 12/24 | 12/24 | | |
| Yang, Mi |
NCT05033587: Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma. |
|
|
| Recruiting | 2 | 28 | RoW | Anlotinib, Anlotinib Hydrochloride Capsules, AK105, Penpulimab Injection, Radiotherapy | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | MGMT-Unmethylated Glioblastoma | 05/23 | 11/23 | | |
| Zhao, Cheng |
NCT05247216: A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis |
|
|
| Completed | 2 | 140 | RoW | Hemay007 800 mg QD group, Hemay007 1200 mg QD group, Hemay007 600 mg QD group, Hemay007 placebo group | Tianjin Hemay Pharmaceutical Co., Ltd | Rheumatoid Arthritis | 06/23 | 06/23 | | |
| Urology, Chief physician of Department of |
NCT05753566: Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer |
|
|
| Not yet recruiting | 2 | 96 | RoW | Rezvilutamide, SHR3680, Androgen deprivation therapy (ADT), SRT | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Jiangsu HengRui Medicine Co., Ltd. | Prostate Cancer, Biochemical Recurrence | 03/27 | 03/28 | | |
| Qiu, Xuefeng |
ARES, NCT05778097: Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence ( Study) |
|
|
| Not yet recruiting | 2 | 103 | RoW | Apalutamide 60mg Tab, Androgen deprivation therapy(ADT) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Xian-Janssen Pharmaceutical Ltd. | Prostate Cancer, Biochemical Recurrence, High Risk | 08/26 | 12/26 | | |
| Tu, Min |
| Not yet recruiting | 3 | 416 | RoW | paclitaxel polymeric micelles for injection, Gemcitabine Hydrochloride for Injection, Paclitaxel for Injection (albumin bound ) | Shanghai Yizhong Pharmaceutical Co., Ltd. | Pancreatic Cancer Metastatic | 07/27 | 12/27 | | |
NCT06361316: Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer |
|
|
| Recruiting | N/A | 53 | RoW | Irinotecan liposome injection, oxaliplatin, Tegafur | Kuirong Jiang, CSPC Ouyi Pharmaceutical Co., Ltd. | Pancreatic Cancer, Adjuvant Therapy | 03/25 | 07/28 | | |
| Wu, Limin |
| No trials found |
